This assay recognizes ?free? IL-18BP unbound to IL-18. Interleukin-18-binding protein (IL-18bp) is a secreted glycoprotein which functions as an antagonist to IL-18. It does this by binding to IL-18 and blocking it from binding to its receptors. IL-18bp shares no homology with the membrane bound IL-18 receptor. IL-18bp isoforms A and C contain a complete Ig domain, while isoforms B and D do not. This domain has been found to be necessary for proper binding function and maintaining its antagonistic characteristics. Expression of IL-18bp is known to be upregulated in patients with Crohn?s Disease, and by the presence of IFN-gamma.
Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma (2023) Shadi Chamseddine, Yehia I. Mohamed, Sunyoung S. Lee, James C. Yao, Clinical Translational Research
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma (2021) Lee CH, Motzer RJ, Glen H, Michaelson MD, Larkin J, Minoshima Y, Kanekiyo M, Ikezawa H, Sachdev P, Dutcus CE, Funashashi Y, Voss MH British Journal of Cancer
Circulating Biomarkers and Outcome from a Randomised Phase Ii Trial of Sunitinib Vs Everolimus for Patients with Metastatic Renal Cell Carcinoma (2016) Voss MH, Chen D, Marker M, Hakimi AA, Lee C-H, Hsieh JJ, Knox JJ, Voi M, Motzer RJ British Journal of Cancer